GSK3B and supranuclear palsy, progressive, 1: Unfortunately, previous clinical trials with unspecific kinase inhibitors (valproic acid, lithium) and the selective GSK3B-inhibitor tideglusib failed to achieve considerable clinical improvements in AD or PSP patients [23, 36, 59].